27 results on '"Fehm, T. N."'
Search Results
2. Long-term survival of HER2-positive breast cancer patients with brain metastases: Subanalysis of the BMBC registry
3. Disseminated tumor cells from the bone marrow of patients with nonmetastatic primary breast cancer are predictive of locoregional relapse
4. DETECT IV - a multicenter, single arm, phase II study evaluating the efficacy of Everolimus in combination with endocrine therapy in patients with HER2-negative, hormone-receptor positive metastatic breast cancer and exclusively HER2-negative circulating tumor cells (CTCs): ID 450
5. DETECT III - a multicenter, randomized, phase III trial to assess efficacy of lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells (CTCs): ID 451
6. Prevalence of circulating tumor cells (CTCs) after adjuvant chemotherapy with or without anthracyclines in patients with HER2-negative early breast cancer (EBC): ID 449
7. The prognostic impact of circulating tumor cells in subtypesof metastatic breast cancer: ID 068
8. SEPTEMBRA - a pilot study to detect and analyze circulating tumor cells in breast cancer patients: ID 332
9. Persistent Triple-Negative Phenotype Is Associated with Poorest Outcome among Patients with Metastatic Breast Cancer (BC) - Results of the Retrospective Multicenter PriMet Study Comparing Molecular BC Phenotypes in Primary Tumors and Corresponding Recurrences
10. The SUCCESS-C trial: Interim analysis of toxicity evaluating the role of an anthracycline-free chemotherapy regimen in the adjuvant treatment of HER2/neu-negative breast cancer.
11. Final multivariate analysis of obesity and survival in patients with node-positive primary breast cancer: The ADEBAR trial.
12. Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay.
13. Systematic comparison of tumor phenotype in primary breast cancer versus corresponding lymph nodes and disease recurrences: Results of the retrospective multicenter WSG/DETECT PriMet study.
14. Pegylated liposomal doxorubicin and carboplatin in malignant mixed epithelial mesenchymal and mesenchymal gynecologic tumors: A phase II trial of the AGO study group.
15. Validation of p95 as a predictive marker for trastuzumab-based therapy in primary HER2-positive breast cancer: A translational investigation from the neoadjuvant GeparQuattro study.
16. Expression of embryonic stem cell factor Sox2 in serous ovarian carcinomas.
17. Prospective evaluation of serum tissue inhibitor of metalloproteinase-1 (TIMP-1) and carbonic anhydrase IX (CAIX) in correlation to circulating tumor cells in patients with metastatic breast cancer.
18. Sentinel-node biopsy before or after neoadjuvant systemic treatment: The German SENTINA trial.
19. Influence of primary systemic therapy on minimal residual disease in primary breast cancer.
20. Bone marrow carcinosis in breast cancer: Clinical presentation, treatment, and prognosis—A single institution review of 22 cases.
21. Effects of bisphosphonates on human osteoblasts as an important constituent of the bone marrow microenvironment.
22. Gestational Trophoblastic Disorders: An Update in 2015.
23. Biomarker für Patientinnen mit metastasiertem Mam makarzinom und das PRAEGNANT-Studiennetzwerk.
24. Apoptotic disseminated tumor cells reflect response to primary chemotherapy in breast cancer
25. HER2 expression in disseminated tumor cells (DTC) and corresponding primary tumors of breast cancer patients
26. Prediction of tumor cell dissemination in primary breast cancer by tumor biological and clinicopathological factors
27. Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.